JJ

Sports and Weather enthusiast

[JJ @JayV80]

@skipsvalue @OTCMarkets Interesting

[JJ @JayV80]

$ZHDM I think that is huge post from the CEO on LinkedIn. Now that the cat is out of the bag... I wonder if he start to see "formal news"? "we hope to announce some exciting developments in the near future”

Three weeks later we see they are working with Abbott. $ABT.TO

[Lee @ldev117]

$ZHDM Knowing Ainnova had prior deals with Roche, and Apollo hospitals, leads me to believe this is $ABT Abbott.
https://t.co/TNZT63Oz3N

https://t.co/x6jk5Q66eY

[JJ @JayV80]

$ZHDM

“It's been months of hard work and very little public communication. We've been focused on a very important stage in our company's journey, and for now, we're not able to share the progress we've made. However, we hope to announce some exciting developments in the near future.

We believe these milestones will mark the beginning of a new phase of growth and expansion, with the potential to create meaningful value for our stakeholders and for the healthcare ecosystem we're helping to build.”

https://t.co/YgB2Va6Am4

[Schito @Schito_74]

$ZHDM, if this is the real Abbot this might get very interesting over time.

[JJ @JayV80]

$ZHDM is like $WPUR. Both have agreements with large companies. “NASA-WPUR” and “ABBOTT-ZHDM”

Only difference is ZHDM tradable float is 6 million vs WPUR over 100 million.

[Lee @ldev117]

$ZHDM Lotto'd some on the Abbott agreement. If this is $ABT abbott labs, on a 6 mill float ticker. Oh boy.

[JJ @JayV80]

@ldev117 $ZHDM keep the DD coming

[Lee @ldev117]

$ZHDM Another partnership with Fortrea to help them on their FDA 510K submission. https://t.co/JEA0eaStVr

[Joe Cazz @Jcazz17]

$ZHDM Next leg over .10 and a test of those 52wk highs

[Lee @ldev117]

$ZHDM Knowing Ainnova had prior deals with Roche, and Apollo hospitals, leads me to believe this is $ABT Abbott.
https://t.co/TNZT63Oz3N

https://t.co/x6jk5Q66eY

[Lee @ldev117]

$ZHDM Lotto'd some on the Abbott agreement. If this is $ABT abbott labs, on a 6 mill float ticker. Oh boy.

[Schito @Schito_74]

$ZHDM, has the potential to be another $TERS, $PRTT, $ACMB, $ADMG, $DAJL and many others for us.

[JJ @JayV80]

@Voyage841918271 @Mineralrite Think about what has to happen to realistically have revenue…

And how many billions of shares will be floating by then?

[JJ @JayV80]

@Voyage841918271 @Mineralrite And there won’t be.

[JJ @JayV80]

@Voyage841918271 @Mineralrite From your Grok post @Voyage841918271

Best-efforts arrangements are therefore common for:
• Capital raises by existing OTC-traded companies (e.g., secondary offerings, Regulation A+/Tier 1 or 2 offerings, private placements that later trade OTC).

[JJ @JayV80]

@Voyage841918271 @Mineralrite Ok… raising $75 million? They talking about a REG Tier 2 several times.

How is 20+ billion shares sustainable?

[JJ @JayV80]

It should matter. Raising $100 million causes more and more dilution. More dilution on a ticker that’s already has a massive amount of shares in the market.
You have to seriously wonder when a reverse split is coming.

Having billions and billions of shares in the float is not sustainable.

[JJ @JayV80]

@Voyage841918271 @Mineralrite Yeah. REG A or S-1 to raise capital $RITE

[JJ @JayV80]

$TAKD
@LysMedical
Lyson Medical Technology holds multiple domestic (Taiwan) and international patents that safeguard its surgical simulation technology. [1, 2]
As a recent spin-off from National Cheng Kung University (NCKU), the company officially finalized the technology transfer of four core foundational patents from NCKU. [1]
The company's patent portfolio primarily focuses on two technological breakthroughs: [1]

1. SimTissue® Biomimetic Material Technology
These patents protect Lyson’s proprietary protein-mimicking polymer formulations (仿蛋白質特性材料). [1, 2, 3]
•What it covers: The chemical composition and manufacturing processes of a synthetic tissue that overcomes the physical limitations of traditional medical plastics. [1]
•Function: It allows the material to replicate the exact mechanical haptic feedback, density, and tactile touch of real human tissues and internal organs. [1, 2]
•Ablation Compatibility: Crucially, this patented formulation reacts to heat exactly like organic tissue, allowing it to withstand and accurately map out thermal distributions during microwave or radiofrequency ablation training without melting artificially. [1, 2]

2. Multi-Functional Highly Simulated Phantom Systems (虛實整合手術訓練平台)
These patents cover the structural engineering and hardware integration of their 3D physical medical simulators. [1, 2]
•What it covers: The mechanical design of individual organ models—such as their transcatheter aortic valve implantation (TAVI) platform, male endourology trainers, and head/neck thyroid models. [1]
•Function: The patents safeguard how these physical phantoms integrate with external tech, such as simulated fluid circulatory systems (to mimic realistic bleeding/blood flow) and Mixed Reality (MR)digital twins for real-time tracking

[JJ @JayV80]

$TAKD a ton to unpack here. Off their new website:
Unified Corporate Structure
The relationship between all three entities functions seamlessly together:
•TransAKT Group: The overarching international parent company setting the strategic direction. [1]
•Lyson Medical Technology: The R&D innovation hub providing the patented SimTissue® biomimetic training models and AI surgical planning interfaces. [1, 2]
•Eric Biotech: The local subsidiary acting as the strategic distributor and partner to deploy these advanced ablation technologies directly to clinics and specialized networks. [1]

Website-https://t.co/xo6zDajiQB